Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

An2 Therapeutics Inc (ANTX)

An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,843
  • Shares Outstanding, K 29,879
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,730 K
  • EBIT $ -67 M
  • EBITDA $ -70 M
  • 60-Month Beta -0.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.24
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +61.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9750 +26.15%
on 11/18/24
1.4600 -15.75%
on 11/21/24
+0.1500 (+13.89%)
since 10/21/24
3-Month
0.9750 +26.15%
on 11/18/24
1.4600 -15.75%
on 11/21/24
+0.1300 (+11.82%)
since 08/21/24
52-Week
0.8700 +41.38%
on 08/09/24
22.2200 -94.46%
on 01/10/24
-15.7200 (-92.74%)
since 11/21/23

Most Recent Stories

More News
Insider Purchase: Director at $ANTX (ANTX) Buys 5,000 Shares

Joseph S Zakrzewski, a director at $ANTX ($ANTX), bought 5,000 shares of the company on 11-19-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

ANTX : 1.2300 (-5.38%)
The Five Biotech Stocks Every Investor Should Know About

Avalon GloboCare Corp., (NASDAQ: ALBT) a developer of innovative precision diagnostics and provider of clinical laboratory services just announced that the United States Patent and Trademark Office (USPTO)...

ALBT : 2.65 (-4.68%)
INSM : 73.81 (+1.57%)
VIR : 6.95 (+3.12%)
CODX : 1.0600 (+1.92%)
ANTX : 1.2300 (-5.38%)
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours

With a rising prevalence of chronic diseases, we’re starting to see higher demand for clinical lab services. That being said, it’s no surprise that, according to Market.Us, the global market for clinical...

INSM : 73.81 (+1.57%)
VIR : 6.95 (+3.12%)
CODX : 1.0600 (+1.92%)
ANTX : 1.2300 (-5.38%)
ALBT : 2.65 (-4.68%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 6.95 (+3.12%)
VBIV : 0.0653 (-50.87%)
ANTX : 1.2300 (-5.38%)
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 1.2300 (-5.38%)
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported...

ANTX : 1.2300 (-5.38%)
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 6.95 (+3.12%)
VBIV : 0.0653 (-50.87%)
ANTX : 1.2300 (-5.38%)
AN2 Therapeutics to Participate in Upcoming Investor Conferences

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 1.2300 (-5.38%)
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 1.2300 (-5.38%)
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an...

ANTX : 1.2300 (-5.38%)

Business Summary

AN2 Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing treatments for rare, chronic and serious infectious diseases with high unmet needs. AN2 Therapeutics Inc. is based in MENLO PARK, Calif.

See More

Key Turning Points

3rd Resistance Point 1.6533
2nd Resistance Point 1.5567
1st Resistance Point 1.3933
Last Price 1.2300
1st Support Level 1.1333
2nd Support Level 1.0367
3rd Support Level 0.8733

See More

52-Week High 22.2200
Fibonacci 61.8% 14.0643
Fibonacci 50% 11.5450
Fibonacci 38.2% 9.0257
Last Price 1.2300
52-Week Low 0.8700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar